Medimmune Limited

Adc Therapeutics Sa

Bergenbio Asa

Medimmune Limtied

Patricius Hendrikus Cornelis Van Berkel

Philip Wilson Howard

John Hartley

Jens Wuerthner

Francesca Zammarchi

Jay Marshall Feingold

Francois Bertelli

David G Williams

Lisa Skelton

This disclosure relates to antibodies that specifically bind to the Interleukin-13 receptor subunit alpha-2 (IL13Rα2) protein, and associated uses and methods for production.

Anti-IL13Rα2 antibodies

A conjugate of formula (I):Ab-(DL)&#x2003;&#x2003;(I)wherein:

Pyrrolobenzodiazepine-antibody conjugates

Conjugates of an antibody that binds to CD25 with PBD dimers.

Conjugates of an antibody that binds to CD19 with PBD dimers.

Site-specific antibody-drug conjugates are described, in particular conjugates comprising pyrrolobenzodiazepines (PBDs) having a labile protecting group in the form of a linker. The site of conjugation, along with modification of the antibody moiety, allows for improved safety and efficacy of the ADC.

Site-specific antibody-drug conjugates

The disclosure provides conjugates of an isolated humanized anti-CD22 antibody and PBD dimers.

Pyrrolobenzodiazepine-anti-CD22 antibody conjugates

A conjugate of formula (I): Ab-(DL)wherein: Ab is an antibody, or an active fragment of an antibody; DL is (II). 

The present disclosure relates to combination therapies for the treatment of pathological conditions, such as cancer. In particular, the present disclosure relates to combination therapies comprising treatment with an Antibody Drug Conjugate (ADC) and a secondary agent.

Combination therapy with an anti-CD25 antibody-drug conjugate

The present invention relates to pyrrolobenzodiazepines (PBDs) having a labile protecting group in the form of a linker to an antibody.

A conjugate of formula (T): Ab-(DL)wherein: Ah is an antibody that hinds to AXL; DL is formula (A). 

Growing community of inventors

Epalinges, Switzerland

Patricius Hendrikus Cornelis Van Berkel